Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
Benjamin Baur, Christoph Solbach, Elena Andreolli, Gordon Winter, Hans-Jürgen Machulla, Sven N Reske, Benjamin Baur, Christoph Solbach, Elena Andreolli, Gordon Winter, Hans-Jürgen Machulla, Sven N Reske
Abstract
Since prostate-specific membrane antigen (PSMA) has been identified as a diagnostic target for prostate cancer, many urea-based small PSMA-targeting molecules were developed. First, the clinical application of these Ga-68 labelled compounds in positron emission tomography (PET) showed their diagnostic potential. Besides, the therapy of prostate cancer is a demanding field, and the use of radiometals with PSMA bearing ligands is a valid approach. In this work, we describe the synthesis of a new PSMA ligand, CHX-A''-DTPA-DUPA-Pep, the subsequent labelling with Ga-68, Lu-177 and Y-90 and the first in vitro characterization. In cell investigations with PSMA-positive LNCaP C4-2 cells, KD values of ≤14.67 ± 1.95 nM were determined, indicating high biological activities towards PSMA. Radiosyntheses with Ga-68, Lu-177 and Y-90 were developed under mild reaction conditions (room temperature, moderate pH of 5.5 and 7.4, respectively) and resulted in nearly quantitative radiochemical yields within 5 min.
Figures
References
- Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011;61:212–236. doi: 10.3322/caac.20121.
- Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide n-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel n-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 1987;262:14498–14506.
- Olson W.C., Heston W.D., Rajasekaran A.K. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev. Recent Clin. Trials. 2007;2:182–190. doi: 10.2174/157488707781662724.
- Hao G., Zhou J., Guo Y., Long M.A., Anthony T., Stanfield J., Hsieh J.T., Sun X. A cell permeable peptide analog as a potential-specific pet imaging probe for prostate cancer detection. Amino Acids. 2011;41:1093–1101. doi: 10.1007/s00726-010-0515-5.
- Su S.L., Huang I.P., Fair W.R., Powell C.T., Heston W.D. Alternatively spliced variants of prostate-specific membrane antigen rna: Ratio of expression as a potential measurement of progression. Cancer Res. 1995;55:1441–1443.
- Wernicke A.G., Varma S., Greenwood E.A., Christos P.J., Chao K.S.C., Liu H., Bander N.H., Shin S.J. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2013 doi: 10.1111/apm.12195.
- Kularatne S.A., Venkatesh C., Santhapuram H.K., Wang K., Vaitilingam B., Henne W.A., Low P.S. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J. Med. Chem. 2010;53:7767–7777.
- Malik N., Machulla H.J., Solbach C., Winter G., Reske S.N., Zlatopolskiy B. Radiosynthesis of a new psma targeting ligand ([18f]fpy-dupa-pep) Appl. Radiat. Isot. 2011;69:1014–1018. doi: 10.1016/j.apradiso.2011.03.041.
- Eder M., Schafer M., Bauder-Wust U., Hull W.E., Wangler C., Mier W., Haberkorn U., Eisenhut M. 68ga-complex lipophilicity and the targeting property of a urea-based psma inhibitor for pet imaging. Bioconjug. Chem. 2012;23:688–697. doi: 10.1021/bc200279b.
- Stabin M.G., Siegel J.A. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310. doi: 10.1097/00004032-200309000-00006.
- Van Essen M., Krenning E.P., de Jong M., Valkema R., Kwekkeboom D.J. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723–734. doi: 10.1080/02841860701441848.
- Kwekkeboom D.J., Teunissen J.J., Bakker W.H., Kooij P.P., de Herder W.W., Feelders R.A., van Eijck C.H., Esser J.P., Kam B.L., Krenning E.P. Radiolabeled somatostatin analog [177lu-dota0,tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005;23:2754–2762.
- Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., Maecke H.R., Muller J. Yttrium-90 dotatoc: First clinical results. Eur. J. Nucl. Med. 1999;26:1439–1447. doi: 10.1007/s002590050476.
- Kosmas C., Snook D., Gooden C.S., Courtenayluck N.S., Mccall M.J., Meares C.F., Epenetos A.A. Development of humoral immune-responses against a macrocyclic chelating agent (dota) in cancer-patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 1992;52:904–911.
- Kodama M., Koike T., Mahatma A.B., Kimura E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-n,n',n'',n''',n''''-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-n,n',n'',n''',n'''',n'''''-hexaacetic acid. Inorg. Chem. 1991;30:1270–1273. doi: 10.1021/ic00006a021.
- Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for pet and spect imaging of disease. Chem. Rev. 2010;110:2858–2902. doi: 10.1021/cr900325h.
- Kobayashi H., Wu C., Yoo T.M., Sun B.F., Drumm D., Pastan I., Paik C.H., Gansow O.A., Carrasquillo J.A., Brechbiel M.W. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of chx-dtpa-conjugated monoclonal antibodies. J. Nucl. Med. 1998;39:829–836.
- Winter G., Zlatopolskiy B., Kull T., Bertram J., Genze F., Cudek G., Machulla H.-J., Reske S. 68ga-dota-dupa-pep as a new peptide conjugate for molecular imaging of prostate carcinoma. J. Nucl. Med. Meet. Abstr. 2011;52:1597.
- Reske S.N., Winter G., Baur B., Machulla H.J., Kull T. Comment on afshar-oromieh et al.: Pet imaging with a [68ga]gallium-labelled psma ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 2013;40:969–970. doi: 10.1007/s00259-013-2385-z.
- Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H.G., Hadaschik B.A., Holland-Letz T., Giesel F.L., Kratochwil C., Haufe S., et al. Pet imaging with a [68ga] gallium-labelled psma ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 2013;40:486–495. doi: 10.1007/s00259-012-2298-2.
- Meyer G.J., Macke H., Schuhmacher J., Knapp W.H., Hofmann M. 68a-labelled dota-derivatised peptide ligands. Eur. J. Nucl. Med. Mol. Imaging. 2004;31:1097–1104.
Source: PubMed